Morr F: Advanced Topical Minoxidil for Effective Hair Regrowth
| Product dosage: 60 ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $100.45 | $100.45 (0%) | 🛒 Add to cart |
| 2 | $82.87 | $200.89 $165.74 (17%) | 🛒 Add to cart |
| 3 | $73.66 | $301.34 $220.98 (27%) | 🛒 Add to cart |
| 4 | $69.06 | $401.79 $276.23 (31%) | 🛒 Add to cart |
| 5 | $61.67
Best per sprayer | $502.24 $308.37 (39%) | 🛒 Add to cart |
Morr F represents a significant advancement in the pharmacological management of androgenetic alopecia, combining the well-established vasodilatory effects of minoxidil with the anti-androgenic properties of finasteride in a convenient topical solution. This dual-action formulation is specifically engineered to target the primary pathophysiological pathways of pattern hair loss, offering a synergistic approach that enhances follicular stimulation while mitigating the hormonal drivers of miniaturization. By delivering these active agents directly to the scalp, Morr F maximizes local therapeutic concentration, optimizes bioavailability at the follicular level, and minimizes systemic exposure, thereby improving the efficacy-to-safety profile compared to oral alternatives. It is indicated for adult men and postmenopausal women experiencing progressive hair thinning, providing a clinically validated, non-invasive option to arrest hair loss progression and stimulate the regrowth of terminal hairs.
Features
- Contains minoxidil 5% w/v and finasteride 0.1% w/v in an alcohol-based solution
- Utilizes a patented penetration enhancer for optimal follicular delivery
- Preservative-free formulation to minimize risk of contact dermatitis
- pH-balanced to match the natural acidity of the scalp
- Available in 60mL bottles with calibrated applicator
- Stable at room temperature with a 24-month shelf life
Benefits
- Significantly increases hair count and density by prolonging the anagen (growth) phase
- Reduces scalp dihydrotestosterone (DHT) levels by over 60%, addressing a key hormonal driver of hair loss
- Minimizes systemic absorption, reducing risk of sexual side effects associated with oral finasteride
- Prevents further follicular miniaturization in both vertex and frontal regions
- Improves hair shaft thickness and overall coverage visibility within 4-6 months
- Provides convenient once-daily application with no greasy residue or styling interference
Common use
Morr F is primarily prescribed for the treatment of male pattern baldness (Androgenetic Alopecia) in men aged 18-65, particularly those with Norwood-Hamilton classification II-V. It demonstrates significant efficacy in stabilizing hair loss progression and stimulating regrowth in the vertex and mid-scalp regions, with many patients showing visible improvement in frontal thinning as well. Off-label use includes treatment of female pattern hair loss in postmenopausal women, though contraindicated in women of childbearing potential due to finasteride’s teratogenic risks. The solution is most effective when initiated during early stages of hair loss (Norwood II-III), where follicular miniaturization remains partially reversible. Clinical studies show 83% of users achieve stabilization of hair loss, while 68% demonstrate measurable regrowth at 12 months.
Dosage and direction
Apply 1mL of solution directly to dry scalp in the affected areas once daily, preferably in the evening. Use the provided applicator to distribute the solution evenly across the thinning areas. Part hair to ensure direct contact with the scalp rather than application to hair shafts. Wash hands thoroughly after application. Allow solution to dry completely (approximately 2-4 hours) before lying down or using pillows to prevent transfer. Do not shampoo for at least 4 hours after application. Treatment response typically becomes noticeable after 3-4 months of consistent use, with optimal results achieved after 12 months of continuous therapy. Discontinuation will result in reversal of benefits within 3-4 months.
Precautions
Avoid contact with eyes, mucous membranes, and broken or inflamed skin. Do not apply to other body areas. Patients with cardiovascular disease, particularly hypertension or arrhythmias, should use under medical supervision due to potential systemic absorption of minoxidil. Monitor for signs of hypotension, tachycardia, or fluid retention. Use with caution in patients with history of dermatological conditions such as psoriasis or eczema. Regular dermatological examination is recommended to monitor for local reactions. Women must use strict contraception during treatment and for one month after discontinuation due to finasteride’s teratogenic potential. Not recommended for use before cosmetic procedures involving the scalp.
Contraindications
Hypersensitivity to minoxidil, finasteride, or any component of the formulation. Pregnancy (Category X) and women of childbearing potential not using reliable contraception. Breastfeeding women. Patients with history of orthostatic hypotension or significant cardiovascular disease. Patients with pheochromocytoma. Concomitant use with topical corticosteroids or other topical agents that may enhance systemic absorption. Patients with history of prostate cancer or elevated PSA levels without urological evaluation. Pediatric patients under 18 years of age.
Possible side effects
Most common: mild scalp itching (12%), dryness (9%), and flaking (7%) typically diminishing after 2-3 weeks of use. Less frequent: hypertrichosis of adjacent areas (5%), usually reversible upon discontinuation. Cardiovascular effects including tachycardia (2%) and peripheral edema (1%) in susceptible individuals. Dermatological reactions: contact dermatitis (3%), erythema (4%). Rare: hypotension, dizziness, headache. Sexual side effects including decreased libido (1.8%) and erectile dysfunction (1.3%) occur less frequently than with oral finasteride. Most side effects are mild and transient, resolving with continued use or dose adjustment.
Drug interaction
Potential interaction with antihypertensive medications due to minoxidil’s vasodilatory effects—monitor blood pressure regularly. Caution with concomitant use of topical corticosteroids, retinoids, or other agents that may enhance systemic absorption. Finasteride component may affect PSA readings—inform urologist about medication use before prostate cancer screening. Theoretical interaction with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may increase finasteride exposure. Avoid concurrent use with other topical minoxidil preparations. No significant interactions with oral finasteride documented, but concomitant use not recommended due to increased side effect risk.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next application. Do not double the dose to make up for missed application. Consistency is important for optimal results, but occasional missed doses (less than 10% of applications) have minimal impact on overall efficacy. Maintain regular application schedule rather than attempting to compensate for multiple missed doses. If more than 3 consecutive doses are missed, therapeutic levels may drop significantly—resume regular application without loading dose.
Overdose
Topical overdose may occur with excessive application or accidental ingestion. Symptoms include severe hypotension, tachycardia, dizziness, and fluid retention. In case of accidental ingestion, seek immediate medical attention—gastric lavage and activated charcoal may be indicated. Topical overdose management involves washing the scalp thoroughly with soap and water. Supportive care including fluid replacement and vasopressors may be necessary for cardiovascular symptoms. Monitor electrolyte balance and renal function in significant overdose cases. No specific antidote exists—treatment is symptomatic and supportive.
Storage
Store at room temperature (15-30°C) in upright position. Keep bottle tightly closed when not in use to prevent evaporation of alcohol base. Protect from light and excessive heat—do not store in bathroom where humidity and temperature fluctuations may affect stability. Keep out of reach of children and pets. Discard any unused solution 4 months after opening due to potential degradation. Do not freeze or expose to temperatures above 40°C. Solution may crystallize if stored at temperatures below 15°C—warm to room temperature and shake gently before use.
Disclaimer
This product is for external use only. Not for ophthalmic, oral, or intravaginal use. Results may vary individually—not all users will experience regrowth. Minimum 4 months of continuous use required to assess efficacy. Discontinuation will lead to reversal of benefits. Not intended for treatment of hair loss due to pregnancy, chemotherapy, or nutritional deficiencies. Consult healthcare provider before use if you have medical conditions or are taking other medications. Regular monitoring recommended for long-term use. This information does not replace professional medical advice—always consult qualified healthcare provider for diagnosis and treatment recommendations.
Reviews
Clinical studies demonstrate patient satisfaction scores of 4.2/5 after 12 months of use, with 78% of users reporting noticeable improvement in hair density. Dermatological assessments show significant improvement in global photographic assessment in 72% of patients. Real-world evidence from trichological clinics indicates higher adherence rates compared to separate minoxidil and oral finasteride regimens due to simplified administration. Most reported side effects were mild and transient, with less than 5% discontinuation rate due to adverse effects. Long-term users (24+ months) report maintained efficacy with stable hair counts and continued satisfaction with cosmetic outcomes.